We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer.
- Authors
Berek, Jonathan; Taylor, Peyton; McGuire, William; Smith, L Mary; Schultes, Birgit; Nicodemus, Christopher F
- Abstract
This phase III study tested the hypothesis that the CA-125-specific murine monoclonal antibody, oregovomab, administered as a monoimmunotherapy after front-line therapy in a selected ovarian cancer population would prolong time to relapse (TTR) and, ultimately, survival.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Vol 27, Issue 3, p418
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2008.17.8400